Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

BACKGROUND: Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Husain, Mansoor, Consoli, Agostino, De Remigis, Alessandra, Pettersson Meyer, Anna Sina, Rasmussen, Søren, Bain, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052629/
https://www.ncbi.nlm.nih.gov/pubmed/35484580
http://dx.doi.org/10.1186/s12933-022-01489-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052629/
https://www.ncbi.nlm.nih.gov/pubmed/35484580
http://dx.doi.org/10.1186/s12933-022-01489-6

Ejemplares similares